Statement of Organization, Functions, and Delegations of Authority, 63437-63438 [2024-17131]
Download as PDF
<![CDATA[
63437
Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices
Medical Education (OCRTME) at the
NIH Clinical Center and the extent to
which this training promotes (a) patient
safety; (b) research productivity and
independence; and (c) future career
development within clinical,
translational, and academic research
settings. The information received from
respondents is presented to, evaluated
clinical research training and medical
education of the highest quality to each
trainee.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours 537.
by, and incorporated into the ongoing
operational improvement efforts of the
Director of the Office of Clinical
Research Training and Education, and
the Chief Executive Officer of the NIH
Clinical Center. This information will
enable the ongoing operational
improvement efforts of the OCRTME
and its commitment to providing
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total annual
burden hours
Type of respondents
Clinical Research Training Program/Medical Research Scholars Program Alumni Survey.
Graduate Medical Education Graduate Survey ....
Clinical Electives Program 1 Year Alumni Survey
Continuing Medical Education Evaluation Survey
Physicians ....................
800
1
20/60
267
Physicians ....................
Physicians ....................
Physicians ....................
350
100
720
1
1
1
20/60
20/60
10/60
117
33
120
Total ...............................................................
.......................................
1,970
1,970
........................
537
Frederick D. Vorck, Jr.,
Project Clearance Liaison, NIH Clinical
Center, National Institutes of Health.
[FR Doc. 2024–17191 Filed 8–2–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Statement of Organization, Functions,
and Delegations of Authority
Substance Abuse and Mental
Health Services Administration
(SAMHSA).
ACTION: Organization, functions, and
delegations of authority.
AGENCY:
SAMHSA has modified its
organizational structure.
SUPPLEMENTARY INFORMATION: Part M of
the Substance Abuse and Mental Health
Services Administration (SAMHSA)
Statement of Organization, Functions,
and Delegations of Authority for the
Department of Health and Human
Services at 71 FR 19740–19741, April
17, 2006, is amended to reflect changes
of the functional statements for the
Center for Substance Abuse Treatment
(CSAT). This amendment reflects the
addition of one new division and two
branches. CSAT has taken the lead in
addressing the substance use disorder
(SUD) treatment needs of Americans,
focusing primarily on opioid treatment,
developing a crisis continuum,
improving adult and adolescent
substance use treatment, and increasing
access to and the quality of SUD
treatment and recovery services. CSAT
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Number of
respondents
Form name
VerDate Sep<11>2014
18:38 Aug 02, 2024
Jkt 262001
is dedicated to collaborating with
grantees and stakeholders to enhance
the accessibility of innovative services
and evidence-based treatment
modalities through grants and technical
assistance.
In order to enhance administrative
and operational efficiencies, CSAT
proposes that each supervisor within
the center should have a staff to
supervisor ratio of 1 supervisor to 10
staff person or less. There is currently a
twelve to one staff to supervisor ratio in
the Division of Services Improvement
(DSI)—with one branch having 17 staff.
Managing 10 or more employees can be
challenging for a first-line supervisor,
who must effectively handle employee
management and oversee grants and
contracts. By adding the Division of
Health Systems Improvement (DHSI)
and two branches, Integrated Care
Branch (ICB) and Opioid Treatment
Branch (OTB) the staff to supervisor
ratio would decrease to eight to one.
Moreover, streamlined and smaller
divisions/branches, with specific focus
areas, will provide additional oversight
and management by the second-level
supervisor for these important Federal
grants and contracts.
Center for Substance Abuse Treatment
Division of Health Systems
Improvement
The proposed DHSI will focus on
equity, medications for opioid use
disorder (MOUD), and the continuum of
care consistent with and necessary for
the achievement of goals outlined in the
President’s Unity Agenda and the Office
of National Drug Control Policy’s
National Drug Control Strategy. Refining
the alignment of grant portfolios by the
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
scope and span of grants and function,
subject matter areas, age group focus
(adolescents versus adults), and
geographic focus (community versus
state) will allow for improved
efficiencies and service. The two
branches in DHSI will be ICB and OTB.
The new division will allow for
dedicated leadership focusing on opioid
treatment, developing a crisis
continuum, improving adult and
adolescent substance use treatment, and
increasing access to and the quality of
SUD treatment and recovery services.
The proposed new division and two
new branches are better aligned based
on content and goal; the major grant
programs impacted by this change are
described below.
ICB will primairly focus on increasing
access to and improving the quality of
services of comprehensive, coordinated,
patient-centered care across the
continuum. The branch will manage the
Minority AIDS Initiative (MAI) and
Screening, Brief Intervention, and
Referral to Treatment (SBIRT) programs
both of which are authorized under the
Public Health Service Act (PHSA), title
V, section 509. MAI seeks to increase
engagement in care for racial and ethnic
underrepresented individuals with SUD
and/or co-occurring substance use and
mental disorders (COD) who are at risk
for or living with HIV/AIDS and receive
HIV/AIDS services/treatment. SBIRT is
a comprehensive, integrated, public
health approach to the delivery of early
intervention and treatment services for
persons with substance use disorders, as
well as those who are at risk of
developing these disorders.
• OTB will primarily focus on
providing evidence-based
E:\FR\FM\05AUN1.SGM
05AUN1
63438
Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices
lotter on DSK11XQN23PROD with NOTICES1
comprehensive care to individuals with
opioid use disorder (OUD), reduce
harm, and effectively address the opioid
crisis through service grants primarily to
community-based organizations. This
includes service grants that support the
provision of MOUD such as methadone,
buprenorphine and naltrexone which
allow patients to receive treatment
while maintaining their daily
responsibilities and lives. Work in this
branch will include engaging in
community outreach and education
efforts to raise awareness about the
opioid epidemic, prevention strategies,
and available treatment options. This is
different from the work done in our
state-based funding programs (State
Opioid Response and Substance Use
Prevention, Treatment, and Recovery
Services Block Grants) which are
housed in the Division of State and
Community Systems (DSCS) and
separate from the focus of the Division
of Pharmacologic Therapies (DPT)
which works with Opioid Treatment
Programs to provide regulatory and
provider support and does not fund
opioid treatment. There is no overlap in
the work of the existing divisions, DSCS
and DPT, and the proposed OTB within
the proposed DHSI. The OTB will
manage the Medication-Assisted
Treatment—Prescription Drug and
Opioid Addiction (MAT–PDOA) and
Targeted Capacity Expansion: Special
Projects (TCE–SP) programs, both of
which are authorized under section 509
of the PHSA, as amended. The purpose
of MAT–PDOA is to provide resources
to help expand and enhance access to
MOUD. It is expected that this program
will help to (1) increase access to
MOUD for individuals with OUD,
including individuals from diverse
racial, ethnic, sexual and gender
minority communities; and (2) decrease
illicit opioid use and prescription
opioid misuse. The purpose of TCE–SP
is to implement targeted strategies for
the provision of SUD or COD harm
reduction, treatment, and/or recovery
support services to support an underresourced population or unmet need
identified by the community.
Delegations of Authority
All delegations and redelegations of
authority to officers and employees of
SAMHSA which were in effect
immediately prior to the effective date
of this reorganization shall continue to
be in effect.
Authority: 44 U.S.C. 3101.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2024–17131 Filed 8–2–24; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
18:38 Aug 02, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: Drug and Alcohol
Warning Network (DAWN) (OMB No.
0930–0078)—Reinstatement With
Change
Under the Public Health Service Act
(42 U.S.C. 290aa–4), SAMHSA is
authorized to collect data on the number
of individuals admitted to the
emergency rooms of hospitals as a result
of the abuse of alcohol or other drugs.
DAWN is a nationwide public health
surveillance system to improve hospital
emergency department (ED) monitoring
of substance use-related visits. It
captures data on ED visits related to
recent substance use and misuse
directly from the electronic health
records (EHR) of participating hospitals.
The new DAWN helps SAMHSA and
public health professionals, clinicians,
and policymakers respond effectively to
the opioid and substance misuse crisis
in the United States.
SAMHSA is requesting OMB approval
of reinstatement with change of the
DAWN data collections, to include
following changes:
• Revise the data collection title to
‘‘Drug and Alcohol Warning Network’’,
replacing existing ‘abuse’ term and
including ‘‘alcohol’’ in the title.
• Remove drug-related death
investigation records review component
administered by state medical
examiners (MEs) and individual
medical examiners/coroners (ME/Cs).
• Revise data collection procedures
where participating hospitals can
choose the direct chart review option (at
the contractor’s operation center, homebased abstraction or on site at the
hospital). Hospitals will also have the
opportunity to select the machine
learning with natural language
processing (ML with NLP) option. The
option for hospitals to use their own
staff to abstract DAWN data as they did
in the legacy DAWN is no longer
offered.
• Revise the hospital selection design
of the ED component to a hybrid system
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
that combines sentinel hospitals and
probability-based selection of hospitals
from high priority suburban/rural areas
and from the remaining areas in the
United States.
• Change the reporting and
publication schedule to further increase
the timeliness of the new DAWN data
availability and delivery to SAMHSA.
The new DAWN data are collected on
an ongoing basis and could be available
to SAMHSA on demand. The new
DAWN data are delivered to SAMHSA
and available for analysis at a more
frequent intervals than the legacy
DAWN.
• Propose following changes to the
ED Case Report Form:
Æ Add ‘‘Center for Behavioral Health
Statistics and Quality’’ to specify the
center responsible for DAWN data
collection.
Æ Revise the data collection title to
‘‘Drug and Alcohol Warning Network’’
from ‘‘Drug Abuse Warning Network.’’
Æ Replace prior ‘‘Facility’’ data field
title with ‘‘Hospital Emergency
Department ID’’ to provide more precise
description and ID number of the
DAWN participating hospitals.
Æ Q3 ‘‘Age’’: replace prior option of
‘‘less than 1 year’’ with two detailed
options of ‘‘4 weeks (28 days) or
younger’’ and ‘‘Between 4 weeks and
one year old (>4 weeks, <1 year)’’ to
enable new identification of neonatal
substance issues.
Æ Q4 ‘‘County of Residence’’: revise
data field title from prior ‘‘patient’s
home zip code’’ and add more accurate
description on what data to be collected
and clarify the purpose of data
collection. Add new ‘‘Unable to
determine county’’ option to improve
data accuracy and account for
geographical variation.
Æ Q6 ‘‘Gender Identity’’ and Q7
‘‘Sexual Orientation’’: added to provide
inclusive measures and to align with
SAMHSA’s efforts in enhancing
behavioral health equities among
diverse populations.
Æ Q8 ‘‘Ethnicity’’ and Q9 ‘‘Race’’:
revise prior data field ‘‘Race/Ethnicity’’
to align with OMB 1997 Standards for
Maintaining, Collecting, And Presenting
Federal Data on Race and Ethnicity
(Statistical Policy Directive No. 15) and
to improve data accuracy and
comprehensiveness.
Æ Q10 ‘‘Case Description’’: replace
the word ‘‘drug(s)’’ with ‘‘substance(s)’’
to clarify that the DAWN collects data
on all substances including alcohol.
Add new instruction language of ‘‘Do
not include information that could
identify the patient or hospital’’ to
provide clear instruction and specify the
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 89, Number 150 (Monday, August 5, 2024)]
[Notices]
[Pages 63437-63438]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-17131]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Statement of Organization, Functions, and Delegations of
Authority
AGENCY: Substance Abuse and Mental Health Services Administration
(SAMHSA).
ACTION: Organization, functions, and delegations of authority.
-----------------------------------------------------------------------
SUMMARY: SAMHSA has modified its organizational structure.
SUPPLEMENTARY INFORMATION: Part M of the Substance Abuse and Mental
Health Services Administration (SAMHSA) Statement of Organization,
Functions, and Delegations of Authority for the Department of Health
and Human Services at 71 FR 19740-19741, April 17, 2006, is amended to
reflect changes of the functional statements for the Center for
Substance Abuse Treatment (CSAT). This amendment reflects the addition
of one new division and two branches. CSAT has taken the lead in
addressing the substance use disorder (SUD) treatment needs of
Americans, focusing primarily on opioid treatment, developing a crisis
continuum, improving adult and adolescent substance use treatment, and
increasing access to and the quality of SUD treatment and recovery
services. CSAT is dedicated to collaborating with grantees and
stakeholders to enhance the accessibility of innovative services and
evidence-based treatment modalities through grants and technical
assistance.
In order to enhance administrative and operational efficiencies,
CSAT proposes that each supervisor within the center should have a
staff to supervisor ratio of 1 supervisor to 10 staff person or less.
There is currently a twelve to one staff to supervisor ratio in the
Division of Services Improvement (DSI)--with one branch having 17
staff. Managing 10 or more employees can be challenging for a first-
line supervisor, who must effectively handle employee management and
oversee grants and contracts. By adding the Division of Health Systems
Improvement (DHSI) and two branches, Integrated Care Branch (ICB) and
Opioid Treatment Branch (OTB) the staff to supervisor ratio would
decrease to eight to one. Moreover, streamlined and smaller divisions/
branches, with specific focus areas, will provide additional oversight
and management by the second-level supervisor for these important
Federal grants and contracts.
Center for Substance Abuse Treatment
Division of Health Systems Improvement
The proposed DHSI will focus on equity, medications for opioid use
disorder (MOUD), and the continuum of care consistent with and
necessary for the achievement of goals outlined in the President's
Unity Agenda and the Office of National Drug Control Policy's National
Drug Control Strategy. Refining the alignment of grant portfolios by
the scope and span of grants and function, subject matter areas, age
group focus (adolescents versus adults), and geographic focus
(community versus state) will allow for improved efficiencies and
service. The two branches in DHSI will be ICB and OTB. The new division
will allow for dedicated leadership focusing on opioid treatment,
developing a crisis continuum, improving adult and adolescent substance
use treatment, and increasing access to and the quality of SUD
treatment and recovery services. The proposed new division and two new
branches are better aligned based on content and goal; the major grant
programs impacted by this change are described below.
ICB will primairly focus on increasing access to and improving the
quality of services of comprehensive, coordinated, patient-centered
care across the continuum. The branch will manage the Minority AIDS
Initiative (MAI) and Screening, Brief Intervention, and Referral to
Treatment (SBIRT) programs both of which are authorized under the
Public Health Service Act (PHSA), title V, section 509. MAI seeks to
increase engagement in care for racial and ethnic underrepresented
individuals with SUD and/or co-occurring substance use and mental
disorders (COD) who are at risk for or living with HIV/AIDS and receive
HIV/AIDS services/treatment. SBIRT is a comprehensive, integrated,
public health approach to the delivery of early intervention and
treatment services for persons with substance use disorders, as well as
those who are at risk of developing these disorders.
OTB will primarily focus on providing evidence-based
[[Page 63438]]
comprehensive care to individuals with opioid use disorder (OUD),
reduce harm, and effectively address the opioid crisis through service
grants primarily to community-based organizations. This includes
service grants that support the provision of MOUD such as methadone,
buprenorphine and naltrexone which allow patients to receive treatment
while maintaining their daily responsibilities and lives. Work in this
branch will include engaging in community outreach and education
efforts to raise awareness about the opioid epidemic, prevention
strategies, and available treatment options. This is different from the
work done in our state-based funding programs (State Opioid Response
and Substance Use Prevention, Treatment, and Recovery Services Block
Grants) which are housed in the Division of State and Community Systems
(DSCS) and separate from the focus of the Division of Pharmacologic
Therapies (DPT) which works with Opioid Treatment Programs to provide
regulatory and provider support and does not fund opioid treatment.
There is no overlap in the work of the existing divisions, DSCS and
DPT, and the proposed OTB within the proposed DHSI. The OTB will manage
the Medication-Assisted Treatment--Prescription Drug and Opioid
Addiction (MAT-PDOA) and Targeted Capacity Expansion: Special Projects
(TCE-SP) programs, both of which are authorized under section 509 of
the PHSA, as amended. The purpose of MAT-PDOA is to provide resources
to help expand and enhance access to MOUD. It is expected that this
program will help to (1) increase access to MOUD for individuals with
OUD, including individuals from diverse racial, ethnic, sexual and
gender minority communities; and (2) decrease illicit opioid use and
prescription opioid misuse. The purpose of TCE-SP is to implement
targeted strategies for the provision of SUD or COD harm reduction,
treatment, and/or recovery support services to support an under-
resourced population or unmet need identified by the community.
Delegations of Authority
All delegations and redelegations of authority to officers and
employees of SAMHSA which were in effect immediately prior to the
effective date of this reorganization shall continue to be in effect.
Authority: 44 U.S.C. 3101.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2024-17131 Filed 8-2-24; 8:45 am]
BILLING CODE P
